Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Yissum Presents Promising Pre-Clinical Results for Oral Delivery of the Anti-Cancer Drug Docetaxel Using a Novel Nanotechnology Approach: Findings published in the prestigious journal "Cancer Research"

Abstract:
Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today successful pre-clinical data of oral delivery of Docetaxel, an anti-cancer drug, utilizing a novel nanotechnology platform. The technology, invented by Professor Simon Benita, Head of Institute for Drug Research, the School of Pharmacy, Faculty of Medicine at the Hebrew University, enables controlled drug release and increased bioavailability of orally administered lipophilic drugs. The findings were published by the prestigious Cancer Research journal (cancerres.aacrjournals.org/content/early/2011/02/25/0008-5472.CAN-10-3118.abstract).

Yissum Presents Promising Pre-Clinical Results for Oral Delivery of the Anti-Cancer Drug Docetaxel Using a Novel Nanotechnology Approach: Findings published in the prestigious journal "Cancer Research"

Jerusalem, Israel | Posted on April 12th, 2011

Oral administration of lipophilic drugs is particularly challenging because they are both metabolized and actively expelled from the intestine. One of the main culprits is a protein pump called P-glycoprotein that transports the drugs back into the intestinal lumen after they have been absorbed into the body. One such lipophilic drug is Docetaxel, an anticancer drug widely prescribed for the treatment of various types of solid tumor cancer. Docetaxel is poorly soluble in water and vigorously pumped out of the intestine wall cells by P-glycoprotein. Therefore, this drug is delivered solely by intravenous infusion, after being solubilized by surfactants, which often increase adverse side effects. The innovative drug delivery technology involves the formation of drug nano-capsules that are then packed in microparticles in a manner that prevents metabolism and expulsion of the drug from the gut. The result is enhanced oral bioavailability along with prolonged release of the drug.

The data of the pre-clinical trials performed on rodents showed that the oral bioavailability of the drug embedded in the novel microparticles was 10 to 20 fold higher than other oral delivery methods, and the levels of the drug were high in the blood stream. Despite the high blood levels achieved, the rats did not suffer from immediate side effects, indicating that the drug did not interact with the gut mucosal tissue. The anti-cancer activity of the novel formulation was demonstrated in cell cultures.

In June 2009, Yissum signed a collaborative agreement with Aurum Ventures MKI, the technology investment arm of Mr. Morris Kahn, for the further development of this oral drug delivery platform.

"Docetaxel is used for the treatment of a variety of cancers, and is currently administered as a high dose infusion every three weeks, resulting in side effects that could be quite severe," said Yaacov Michlin, CEO of Yissum. "Patients in need of this drug will thus greatly benefit from the ability to receive the drug in lower doses using an oral route. The recently published preclinical trials show that Prof. Benita's invention, currently being developed by Aurum Ventures MKI, has a real potential to offer cancer patients an oral delivery route for Docetaxel. The new delivery platform has been previously shown to be effective also for other drugs, and offers a revolutionary method to bypass specific potent barriers in the intestine and the liver, thereby greatly increasing bioavailability."

Prof. Benita added, "This unique system may allow changing the route of administration of highly lipophilic P-glycoprotein substrate drugs from injectable to oral with potentially high bioavailability and lower side effects without affecting the normal physiological activity of the metabolic filters."

####

About Yissum Research Development Company Ltd.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. was founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Products based on Hebrew University technologies that have been commercialized by Yissum currently generate $1.2 Billion in annual sales. Ranked among the top technology transfer companies in the world, Yissum has registered 6100 patents covering 1750 inventions; has licensed out 480 technologies and has spun out 65 companies. Yissum’s business partners span the globe and include companies such as Novartis, Microsoft, Johnson & Johnson, Merck, Intel, Teva and many more.

About Aurum

Aurum Ventures MKI is the technology investment arm of Morris Kahn, a prominent business man, philanthropist and entrepreneur. Aurum Ventures MKI invests in Israeli and Israel related companies in the fields of life sciences and clean-tech in all stages of development. For further information please visit www.aurum.co.il.

For more information, please click here

Contacts:
Yissum Ltd.
Tsipi Haitovsky, Media Liaison
+972-52-598-9892

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

NanoTechnology for Defense (NT4D) October 22nd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Nanomedicine

Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014

Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

‘Designer’ nanodevice could improve treatment options for cancer sufferers October 22nd, 2014

Discoveries

Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014

NIST offers electronics industry 2 ways to snoop on self-organizing molecules October 22nd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Announcements

NanoTechnology for Defense (NT4D) October 22nd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Patents/IP/Tech Transfer/Licensing

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE